Schaefer et al., 2001 - Google Patents
Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and …Schaefer et al., 2001
View PDF- Document ID
- 380074478146627291
- Author
- Schaefer L
- Raslik I
- Gröne H
- Schönherr E
- Macakova K
- Ugorcakova J
- Budny S
- Schaefer R
- Kresse H
- Publication year
- Publication venue
- The FASEB Journal
External Links
Snippet
Small leucine‐rich proteoglycans (SLRPs), for example, decorin, biglycan, fibromodulin, and lumican, are extracellular matrix organizers and binding partners of TGF‐β. Decorin is also involved in growth control and angiogenesis. Hence, these proteoglycans are likely of …
- 102000004237 Decorin 0 title abstract description 131
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schaefer et al. | Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin | |
| Yamada et al. | Perspectives in mammalian IGFBP-3 biology: local vs. systemic action | |
| Shweke et al. | Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-β activation and cell infiltration | |
| JP5068428B2 (en) | Targets for angiogenesis and anti-angiogenic therapy | |
| Zarrinkalam et al. | Connective tissue growth factor and its regulation in the peritoneal cavity of peritoneal dialysis patients | |
| JP2010215636A (en) | Differentiation regulating agent and method for using the same | |
| US7550435B2 (en) | Method of modifying glucose activity using polypeptides selectively expressed in fat tissue | |
| US9802994B2 (en) | Composition for preventing or treating fracture or osteoporosis using slit-robo system | |
| US20150209407A1 (en) | Methods for the treatment and prevention of osteoporosis and bone-related diseases | |
| Chen et al. | High glucose alters proteoglycan expression and the glycosaminoglycan composition in placentas of women with gestational diabetes mellitus and in cultured trophoblasts | |
| JP5640230B2 (en) | New physiological substance NESFATIN and related substances, and their uses | |
| Zhou et al. | The role of chemerin in the regulation of cGAS‐STING pathway in gestational diabetes mellitus placenta | |
| US8455448B2 (en) | Myostatin isoform | |
| WO2004069268A1 (en) | REGENERATION AND NEOGENESIS OF RETINAL VISUAL CELL WITH Otx2 GENE | |
| AU2011249750B2 (en) | Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents | |
| US20110312872A1 (en) | Norrin in the treatment of diseases associated with an increased tgf-beta activity | |
| US20100173314A1 (en) | Diagnostic methods using tenascin-w compositions | |
| JP2010526994A (en) | Methods for detecting in vivo activity of neurotrypsin, use of the method in the diagnosis and monitoring of neurotrypsin-related disorders and use of the C-terminal 22 kDa fragment of agrin as a biomarker | |
| KR20160062517A (en) | A pharmaceutical composition for inhibition of vascular calcification comprising dpp-4 inhibitor as an effective component | |
| Zhao et al. | Canagliflozin Delays Aortic Valve Calcification by Enhancing the AMPK/Nrf2/HO‐1 Antioxidant Signaling Pathway in Valvular Interstitial Cells | |
| US20070134650A1 (en) | Scleraxis | |
| US20090048158A1 (en) | Insulin-Like Growth Factor Binding Protein-4 Compounds and Methods for Inhibiting Angiogenesis and Tumor Growth in Mammalian Cells | |
| Lakota et al. | Serum amyloid A and its potential physiological/pathological functions-an overview of patents | |
| Yamada et al. | Articles in PresS. Am J Physiol Cell Physiol (March 11, 2009). doi: 10.1152/ajpcell. 00598.2008 | |
| Lee | Interactions Between IGFBP-3 and Nuclear Receptors in Prostate Cancer Apoptosis |